Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients
Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients
Shots:
- Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT
- Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS results of PACIFIC trial
- In 2018, AZ received recommendations for Stage III NSCLC US, Canada, Switzerland, India, and Japan based on PACIFIC trial
